Amnis, a 12-year-old Seattle company which provides high-speed cell imaging instruments, has been sold to EMD Millipore for an undisclosed price. EMD is a division of Merck KGaA of Germany, and the company plans to use the technology to grow its presence in the market for image flow cytometry.
Led by co-founder and CEO David Basiji, Amnis employs 40 people and reported sales of $14 million last year.
“The combination of Amnis with EMD Millipore will greatly accelerate development of novel applications in imaging flow cytometry, enhance our customer support, and accelerate product development,” said Basiji in a press release.
Amnis raised an $8.25 million venture round in 2006 from backers that included CVF, MedVenture Associates and OrbiMed Capital. It holds more than three dozen patents on the technology.